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Three monoclonal antibodies,  designated  aIR- 1,  aIR- 
2,  and  aIR-3,  were  prepared by  fusing FO myeloma 
cells  with  spleen cells  from a mouse immunized with a 
partially  purified  preparation f insulin  receptors  from 
human  placenta.  These  antibodies were  characterized 
by their  ability  to  immunoprecipitate solubilized  recep- 
tors labeled  with 1251-insulin or ‘251-somatomedin-C in 
the  presence or absence of various  concentrations of 
unlabeled  insulin or somatomedin-C. aIR- 1 preferen- 
tially immunoprecipitates insulin receptors and also 
less effectively imnoprecipitates somatomedin-C re- 
ceptors,  while  aIR-2  and  aIR-3  preferentially immu- 
noprecipitate somatomedin-C  receptors,  but may also 
weakly  immunoprecipitate  insulin  receptors. 
These  three monoclonal  antibodies, as well as A410, 
a rabbit polyclonal antibody,  were used to  immunopre- 
cipitate  insulin  and somatomedin-C receptors  from sol- 
ubilized  human  lymphoid  (IM-9)  cells and  human  pla- 
centa  membranes  that  had been  lZ5I-labeled  with lac- 
toperoxidase.  Analysis of the immunoprecipitates  by 
sodium  dodecyl  sulfate-polyacrylamide  gel  electropho- 
resis  indicates that both  receptors are composed of a 
and ,B subunits.  The ,B subunit of the insulin  receptor 
(immunoprecipitated  by  aIR- 1 and  A410)  has  slightly 
more  rapid mobility than  the corresponding  subunit of 
the somatomedin-<= receptor (immunoprecipitated by 
aIR-2  and  aIR-3).  Interestingly,  the a subunit of the 
placenta somatomedin-C receptor  has a slightly  faster 
mobility than  its  counterpart  from  IM-9 cells. 
Immunoprecipitation of receptor  that  had  been re- 
duced and  denatured  to  generate isolated subunits  in- 
dicates  that  aIR-2  and  aIR-3  interact  with  the cy sub- 
unit of the somatomedin-C receptor  while A410 inter- 
acts  with  both  subunits of the insulin  receptor. aIR-1 
failed  to  react  with  reduced  and  denatured  receptors. 
Insulin and somatomedin-C’ are structurally related pep- 
tide  hormones  with  overlapping biological activities (1). Each 
binds with high affinity to its own receptor,’ but each can 
also bind with considerably lower affinity  to  the other’s re- 
ceptor (2 -5 ) .  This  cross-reactivity is attributable  to  structural 
* The  costs of publication of this  article were defrayed in  part by 
the  payment of page  charges. This  article  must  therefore be hereby 
marked  “aduertisement”  in  accordance  with 18 U.S.C. Section 1734 
solely to  indicate  this fact. 
like  growth factor I (27). 
Somatomedin-C has been  sequenced and  is  identical  to  insulin- 
‘The receptor which is referred to here as the somatomedin-c 
receptor has also been called the insulin-like growth factor, type I 
receptor  (4).  The  receptor which is  referred  to  here  as  the  insulin- 
like growth factor I1 receptor has also been called the insulin-like 
growth  factor,  type I1 receptor  (4). 
similarities between the receptors as well as between the 
peptides themselves. Both receptors are composed of two 
types of subunits, which have  approximate molecular  weights 
of about 135,000 and 90,000 (3, 4, 6-12). These  are  thought 
to form  disulfide-linked heterotetramers  containing two cop- 
ies of each  type of subunit  (3,4,6-8, 10-12). Antibodies from 
a patient with insulin resistance and acanthosis nigricans 
have  been  shown to  inhibit  the  binding of both insulin and 
somatomedin-C to their respective  receptors,  suggesting that 
the  receptors  are also  immunochemically similar  (13).  Soma- 
tomedin-C also binds with  relatively high affinity  to  insulin- 
like growth factor I1 receptors. This receptor is structurally 
different from somatomedin-C  and  insulin receptors, and  has 
little or no  affinity for insulin (3, 4, 14). 
The  present  studies describe three monoclonal antibodies 
to  insulin  and  somatomedin-C receptors. These  are used to 
investigate  the immunochemical cross-reactivity of the two 
receptors and to identify their subunits in human placenta 
and IM-9 cells. Some properties of cuIR-1 have  been  described 
previously (15). 
MATERIALS  AND  METHODS 
Receptor Purification-Human placenta membranes were solubi- 
lized with 2% Triton X-100, and insulin receptor was purified by 
sequential chromatography on concanavalin A-Sepharose, insulin- 
Sepharose,  and  wheat germ agglutinin-Sepharose (16-18). As previ- 
ously reported by others (10, 19), we found that somatomedin-C 
receptors could be quantitatively recovered in the eluate of the 
concanavalin A column,  and  that  about 30-50% was adsorbed  to  the 
insulin-Sepharose  column. However, no  somatomedin-C binding ac- 
tivity was detected in the  urea  eluate of the  insulin-Sepharose column 
or  at  later  stages of purification, while insulin-binding  activity could 
he followed throughout  the purification  procedure (data  not  shown). 
In view of results to be presented later, somatomedin-C receptors 
may have  been present  but  in a denatured form  incapable of binding 
hormone. To assess  the degree of purity  and  the  amount of protein 
present, a small aliquot of the wheat germ agglutinin eluate was 
reduced and analyzed by SDS3-polyacrylamide gel electrophoresis 
followed by silver staining (20). A 135,000 molecular weight band  and 
faint  minor 90,000- and 45,000-molecular  weight bands were present. 
About 5-10 pg  of receptor protein was obtained  per  placenta. 
Production of Monoclonal Antibodies-Three SJL mice (Jackson 
Laboratories, Bar Harbor, ME) were injected subcutaneously, with 
wheat germ agglutinin-Sepharose  eluate  containing 3 pg of receptor, 
emulsified in an equal volume of complete Freund‘s adjuvant, and 
boosted three times at 3 week intervals with a similar amount of 
purified  receptor  emulsified in incomplete Freund’s adjuvant. All mice 
developed antiserum  that  immunoprecipitated  receptors labeled with 
1251-insulin and 1251-somatomedin-C (see  Table I for details of assay). 
The mouse with the highest titer of antibodies  to  insulin receptors 
received an i.v. boost of 10 Hg of receptor.  Three days later,  it was 
sacrificed and  its lymph node and  spleen cells were fused with FO 
myeloma  cells  (Cell Distribution  Center,  Salk  Institute,  La  Jolla, CA) 
(21). To achieve an  initial cloning stage,  hybrids were seeded a t  a low 
The  abbreviation used is: SDS, sodium dodecyl sulfate. 
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density using peritoneal exudate cells from SJL mice as feeders (21). 
Hybridomas grew to numbers exceeding 1000 cells/cm2/ml of culture 
medium in 26 out of 1000 wells. Supernatants were screened for 
antibodies that immunoprecipitated insulin or somatomedin-C recep- 
tors as described in the legend to Table I. Six wells were initially 
positive for antibodies to insulin receptors. These and only these were 
also positive for antibodies to somatomedin-C receptors. Cell lines 
from three of these wells eventually died out or stopped producing 
antibody. Hybridomas from the remaining three wells were serially 
subcloned by limiting dilution four times. The resulting clones and 
the antibodies they produce have been designated aIR-1,  aIR-2, and 
nIR-3. Antibodies used in this paper were harvested from ascites fluid 
of Balb/C X SJL F, hybrids (Jackson Laboratories) inoculated with 
these cell lines. aIR-1 and aIR-3 were further purified on DEAE- 
cellulose equilibrated with 10 mM potassium phosphate, pH 8.0. nIR- 
2 was retained on DEAE-cellulose under these conditions, and ascites 
fluid was used directly without further purification. 
All three antibodies are IgGl(K) (determined by Mono AB-ID EIA 
Kit, Zymed Laboratories, Burlingame, CA). 
Iodination of Cells and  Membranes-IM-9 cells were labeled with 
I2'I by using lactoperoxidase (22). The labeled cells were  washed with 
phosphate-buffered saline, solubilized by vortexing with 1% Triton 
X-100, and  the labeled glycoproteins purified by wheat germ  agglu- 
tinin-Sepharose as described for placenta. Placenta membranes were 
iodinated with lactoperoxidase as follows: 1 mg  of placenta membrane 
was suspended in 5 ml of phosphate-buffered saline. 100 pg of lacto- 
peroxidase was added followed  by 2 mCi  of [1251]NaI. A 20-p1 aliquot 
of M Hz02 was added every 4 min for 12 min. The membranes 
were then washed 3 times by centrifugation at 50,OGO X g for 30 min 
with 8 ml of phosphate-buffered saline. The membrane pellet was 
solubilized with 2% Triton X-100 in 50 mM Tris.HC1, pH 7.7, 
containing 1 mg/ml of bacitracin and 20 pg/ml of phenylmethylsul- 
phony1 fluoride. After 30 min, the solubilized placenta membranes 
were centrifuged at 100,000 X g for 1 h. The supernatant was diluted 
with three volumes of Tris.HC1, pH 7.7, containing 1 mM CaCI2 and 
1 mM MgC1, and applied to a 0.5-ml wheat germ agglutinin-Sepharose 
column equilibrated with this buffer containing 0.2% Triton X-100. 
The column was  washed with 20 ml  of the Triton-containing buffer, 
and the labeled glycoproteins were eluted with 0.5 M N-acetyl gluco- 
samine in 50 mM Tris.HC1  containing 0.2% Triton X-100, 1 mg/ml 
of bacitracin, and 20 pg/ml of phenylmetbylsulfonyl fluoride. 
RESULTS 
Table I illustrates  the  ability of the  three  monoclonal  an- 
tibodies  to  immunoprecipitate  receptor-bound  1z51-insulin  and 
'"I-somatomedin-C. aIR-1  immunoprecipitates  considerably 
TABLE I 
Immunoprecipitation of receptors labeled with '251-insulin  and '"I- 
somatomedin-C 
Solubilizedplacenta membranes were incubated at 4 "C with 50,000 
cpm of '2'II-insulin or 15,000 cpm of lZsI-somatomedin-C in 0.12 ml of 
50 mM Tris. HCI, pH 7.7, containing 0.1% bovine serum albumin and 
0.1% Triton X-100. In one set of control tubes (+ insulin) 20 pg/ml 
of unlabeled insulin was added with the labeled hormones. In a second 
set of control tubes (- receptor), solubilized placenta was omitted. 
After 18 h, 20 pl of normal mouse serum diluted 1:50 was added alone 
or with (VIR-1 (final concentration 19 pg/ml), aIR-2 (final dilution of 
ascites 1:420), or aIR-3 (final concentration 11 pg/ml). After an 
additional 6 h, 7 pl of anti-mouse serum (Cappel, Cochraneville, PA) 
were added. After 18 h at 4 "C, the immunoprecipitates were  washed 
twice with 4 ml  of the  Tris buffer bv centrifugation at 3,000 X g. 





Normal mouse serum 
nIR-1 + insulin 
(VIR-2 
(VIR-1 - receptor 
(VIR-2 + insulin 
(dR-2 - receptor 
(dR-3 + insulin 
(VIR-3 - receptor 
(VIR-1 
RIR-3 
112 f 8 
20,333 f 362 
124 f 6 
115 f 12 
189 f 36 
115 f 2 
121 f 3 
371 f 11 
128 f 9 
116 f 6 
74 f 11 
864 f 57 
117 f 3 
78 f 6 
1,145 f 37 
402 k 16 
67 f 8 
816 f 15 
164 f 15 
63 f 10 
Insulin and Somatomedin-C 
more bound 1251-insulin and 12511-somatomedin-C than  does 
normal  mouse  serum.  If  solubilized  placenta  is  omitted  from 
the assay (or if it  is heated to 70 "C for 10 min (data not 
shown)), there is no specific immunoprecipitation of either 
labeled  hormone  by  aIR-1.  This  indicates that the  antibody 
is  not  directly  reacting  with  the  hormone (or in  the case of 
somatomedin-C, a binding  protein  in  serum or ascites  fluid), 
but  with  hormone  binding  proteins  present  in  placenta  mem- 
branes.  The  ability of insulin to inhibit  the  immunoprecipi- 
tation of the  labeled  hormones  indicates that these  binding 
proteins are saturable  and  have a relatively  high  affinity  for 
insulin. aIR-2 and aIR-3 both immunoprecipitate more re- 
ceptor-bound '251-insulin than  normal  serum  but  considerably 
less  than  aIR-1.  Both  antibodies  immunoprecipitate  similar 
amounts of bound '"I-somatomedin-C. As with  aIR-1,  spe- 
cific  immunoprecipitation of both  labeled  hormones  by  aIR- 
2 and aIR-3 is dependent on the presence of solubilized 
placenta  and  is  inhibited  by  native  insulin, or by  heat  treating 
the solubilized  placenta  (data  not  shown). 
Receptor Specificity-Since in  these  studies,  'z51-insulin  and 
'"I-somatomedin-C are immunoprecipitated as labeled hor- 
mone-receptor  complexes,  the  potency of unlabeled  hormones 
to  compete  for  receptor  binding,  and  thereby  inhibit  immu- 
noprecipitation of labeled  hormone,  reflects  their  specificity 
for  the  receptor.  This  can  be  used  to  identify  the  receptor  to 
which  the  labeled  hormone  is  bound  when  it  is  immunopre- 
cipitated. 
The  concentrations of unlabeled  insulin  and  somatomedin- 
C that  inhibit  the  immunoprecipitation of Iz5I-insulin  by  aIR- 
1 (Fig. 1A) are  similar  to  those  previously  reported  to  inhibit 
the  binding  of '2511-insulin to  the  insulin  receptor  (2, 4). This  
suggests  that  the '2511-insulin that  is  immunoprecipitated  by 
cuIR-l (Fig. 1A) is  bound  mainly to the  insulin  receptor,  and 
that  aIR-1,  therefore,  recognizes  insulin  receptors.  Similarly, 
the  concentrations of unlabeled  insulin  and  somatomedin-C 
that  inhibit  the  immunoprecipitation of '*'I-somatomedin-C 
by d R - 2   a n d   a I R - 3  (Fig. 1, E and F) are similar to those 
previously  reported  to  inhibit  the  binding of 1251-somatome- 
din-C to the somatomedin-C receptor (2-5). This suggests 
that   aIR-2  and  aIR-3 recognize the  somatomedin-C  receptor. 
The  competition  binding  curves  in  Fig. 1, B,  C, and D are 
more  complex.  Since  '"I-insulin will bind  weakly  to  the 
somatomedin-C  receptor  and  since  aIR-2  and  CYIR-3  immu- 
noprecipitate  the  somatomedin-C  receptor,  it  is  possible  that 
the relatively small amounts of 1z51-insulin immunoprecipi- 
tated  by  these  antibodies  are  bound  entirely  to  somatomedin- 
C receptors. However, the data (Fig. 1, B and C) are not 
consistent with this interpretation. The potency of native 
insulin  to  inhibit  the  immunoprecipitation of 1251-insulin  by 
dR-2   and   CYIR-3  is  too  high,  and  the  potency of unlabeled 
somatomedin-C  is  too  low  (Fig. 1, B and C) for  all  the 
immunoprecipitated "'I-insulin to  be  bound  to  the  somato- 
medin-C  receptor.  Similarly, the potency of unlabeled  insulin 
is  too low and  the  potency of unlabeled  somatomedin-C  is  too 
high  for  the I2'II-insulin immunoprecipitated  by  these  antibod- 
ies to be bound entirely to insulin receptors. The simplest 
explanation  for  these  data  is  that  1251-insulin  immunoprecip- 
itated by mIR-2 and aIR-3 is bound to a combination of 
insulin  receptors  and  somatomedin-C  receptors.  The  flat 
slopes of the  competition  curves  (Fig.  1, B and C) are  consist- 
ent  with  the  presence of more  than  one  type of receptor.  This 
reasoning  suggests that dR-2   and   a IR-3   do   immunoprec ip i -  
tate insulin  receptors,  although at the  concentration of anti- 
body  used,  considerably  less  effectively  than  a1R-1.  Similarly, 
the '251-somatomedin-C immunoprecipitated by aIR-1 (Fig. 
10) appears  to  be  bound  to a mixture of insulin  and  somato- 
medin-C  receptors,  suggesting  that  aIR-1  weakly  recognizes 
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FIG. 1. Specificity  of immunoprecipitated receptors. Solubilized placenta  membranes were incubated as 
indicated  in  Table I with 50,000 cpm of '*'II-insulin (A, E ,  and C) or 15.000 cpm 12'I-somatomedin-C (D ,  E, and F) 
in  the  absence or presence of various  concentrations of unlabeled insulin (0) or somatomedin-C (0). The labeled 
receptors were then  immunoprecipitated as described in  the legend to  Table I by: A and D, nIR-1 (19 pg of IgC/ 
ml); E ,  and E,  nIR-2 (1:420 dilution of ascites); C and F, nIR-3 (11 pg of IgG/ml).  Nonspecific counts  (counts 
immunoprecipitated by normal mouse serum without added monoclonal antibody) have been subtracted in the 
calculations. 
somatomedin-C  receptors. 
To further evaluate which receptors are immunoprecipi- 
tated by each antibody,  placenta  membranes were incubated 
with "'1-somatomedin-C in the  absence of unlabeled  peptides 
(Fig. 2, lanes 1-4), with  100  ng/ml of somatomedin-C (Fig. 2, 
lanes 5-8), with  100  ng/ml of insulin (Fig. 2, lanes 9-12), or 
with both 100 ng/ml of somatomedin-C  and  insulin (Fig. 2, 
lanes 13-26). '2sI-somatomedin-C was then covalently  cross- 
linked to the receptor to which it was bound with  disuccini- 
midyl suberate. The membranes were solubilized with Triton 
X-100, immunoprecipitated with normal mouse serum,  aIR- 
1, aIR-2  or  aIR-3,  and analyzed by SDS-polyacrylamide gel 
electrophoresis. 
aIR-2 and aIR-3 immunoprecipitated a 132,000-Mr band 
that was heavily labeled in the absence of somatomedin-C 
(Fig. 2, lanes 3 and 4).  Labeling of this band was readily 
inhibited by 100 ng/ml of somatomedin-C (Fig. 2, lanes 7 and 
81, but  not  inhibited by 100 ng/ml of insulin (Fig. 2, lanes 11 
and 12). Because of its relative affinity for insulin and  soma- 
tomedin-C and  its  electrophoretic mobility, this  band  appears 
to be the a subunit of the  somatomedin-C receptor. 
In the absence of unlabeled  peptides, the  band immunopre- 
cipitated by aIR-1 (Fig. 2, lane 2) is less heavily labeled than 
those  immunoprecipitated by aIR-2  or  aIR-3.  In  addition,  it 
is broader and  has a portion  with a slightly  slower electropho- 
retic mobility. Furthermore,  its labeling  is  only partially  in- 
hibited by unlabeled somatomedin-C (Fig. 2, lane 6 )  and is 
also partially  inhibited by unlabeled  insulin (Fig. 2, lane IO), 
suggesting that  this  band is  composed of a subunits of both 
insulin and  somatomedin-C receptors. 
When  similar  studies  are  carried  out using lZ5I-insulin as 
the labeled peptide  instead of "'I-somatomedin-C, aIR-1  spe- 
cifically immunoprecipitates a labeled band with a molecular 
weight of 135,000 (Fig. 2, lane 17). Labeling of this  band is 
readily inhibited by 100 ng/ml of insulin (data  not  shown). 
When I2'I-insulin is used as  the labeled peptide, aIR-2  and 
STD1 2 3 4 5 6 7 8 91011121314151617 
FIG. 2. Immunoprecipitation of  affinity  cross-linked recep- 
tor. Placenta  membranes (0.4 mg of protein) were incubated for 90 
min a t  15  "C in 1.0 ml of 20 mM NaPO,, pH 7.4, containing 0.05% 
albumin with lo6 cpm of 12sII-somatomedin-C (lanes 1-16) or I2'I- 
insulin  (lane 17)  and  no  unlabeled  hormone  (lanes 1-4 and 17), 100 
ng/ml of somatomedin-C (lanes 5-S), 100  ng/ml of insulin (lanes 9- 
12), or both 100  ng/ml of somatomedin-C  and  100 ng/ml of insulin 
(lanes 13-16). Then 0.1 mg of disuccinimidyl suberate was added. 
After  30 min,  the disuccinimidyl suberate  was  quenched with 20 pl of 
1 M NH4CI.  4 ml of SO mM Tris. HCI, pH 7.7, containing0.2%  albumin 
was added and the membranes pelleted. The  membrane pellet was 
dissolved in SO mM Tris.HCI containing 2% Triton X-100, with 
bacitracin (1 mg/ml) and  phenylmethylsulfonyl fluoride and  centri- 
fuged for 30 min at 200.000 X g. The  supernatant was  diluted 1:4 with 
Tris.  HCl  containing  bacitracin  and  immunoprecipitated as escribed 
in  the legend to Fig. 1 with  normal mouse serum (lanes I ,  5, 9, and 
13), nIR-1 (lanes 2, 6, IO, 14, and 17), nIR-2 (lanes 3, 7, 11, and 15). 
or nIR-3 (lanes 4,8,12, and 16). The immunoprecipitates were washed 
twice with 4 ml of Tris.  HCl  containing 0.2% Triton X-100 and  once 
with 4 ml of H20. They were then lyophilized and subjected to SDS- 
polyacrylamide gel electrophoresis on a 6.5% gel. The  standards in 
the lefl lanes are myosin heavy chain, phosphorylase, and  albumin. 
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FIG. 3. Immunoprecipitation of labeled receptor from iodinated human placenta membranes and 
IM-9 cells. A, '%I-labeled placenta membrane glycoproteins (1.2 X lo6 cpm) were incubated in 50 mM Tris.HC1, 
pH 7.7, containing 0.2% Triton X-100, 0.1% bovine albumin, 1 mg/ml of bacitracin, and 20 pg/ml of phenyl- 
methylsulfonyl fluoride with: lane I ,  normal mouse serum diluted 1:300, lane 2, normal mouse serum diluted 1:300 
plus aIR-1 (19 pg of I&/ml); lane 3, normal mouse serum diluted 1:300 plus aIR-2 (ascites fluid 1:420); lane 4, 
normal mouse serum diluted 1:300 plus aIR-3 (11 pg of I&/ml); lane 5, 100  pg/ml of preimmune rabbit I&; lane 
6, 85 pg/ml of A410. After 8 h at  4 "C, 20 pI of anti-mouse serum (Cappel) diluted 1:3 was added to  the tubes 
containing mouse immunoglobulin, and 20 pl of fixed staphylococci bearing protein A (Pansorbin) was added to 
tubes  containing  rabbit immunoglobulin, and  the incubation was continued overnight a t  4 "C. The immunoprecip- 
itates were then washed three times with 4 ml of Tris.HC1, containing 0.2% Triton X-100, and once with distilled 
water. The immunoprecipitates were lyophilized and electrophoresed on  a 6.5% SDS-polyacrylamide gel. Shown is 
an autoradiogram of the dried gel. E ,  'lSI-labeled IM-9 cell membrane glycoproteins (3.2 X 10' cpm) immunopre- 
cipitated as described above. Lane I ,  normal mouse serum; lane 2, aIR-1; lane 3, aIR-2; lane 4, aIR-3; lane 5, 
preimmune rabbit I&; lane 6, A410. 
aIR-3 fail to produce detectable specific immunoprecipitation 
of affinity labeled bands (data  not shown). This is consistent 
with the relatively weak ability of aIR-2  or  aIR-3  to immu- 
noprecipitate receptor labeled with '*'II-insulin as is indicated 
by Table I  and Fig. 1. 
Immunoprecipitation of Lactoperoxidase-labeled  Recep- 
tors-To further  demonstrate that these antibodies interact 
directly with receptors for insulin and somatomedin-C, and 
to establish their specificity, we examined their ability to 
immunoprecipitate I2"I-labeled membrane glycoproteins from 
human placenta and IM-9  cells. As previously  described (15), 
aIR-1 specifically immunoprecipitated two polypeptides with 
apparent molecular  weights of 135,000 and 90,000  from both 
human placenta and IM-9  cells  (Fig. 3A, lane 2 and Fig.  3B, 
lane 2). Polypeptides with similar molecular weights were 
immunoprecipitated by A410 (Fig. 3A, lane 6 and Fig. 3B, 
lane 6) ,  a rabbit antiserum to  rat liver insulin receptor (23). 
These bands correspond to  the a and @ subunits of the insulin 
receptor described  previously by several laboratories (6-9,22). 
aIR-2  and  aIR-3 also specifically immunoprecipitate two 
polypeptides with apparent molecular weights of approxi- 
mately  135,000 and 90,000 (Fig. 3A, lanes 3 and 4, and Fig. 
3B, lanes 3 and 4).  Because of the specificity of aIR-2  and 
aIR-3, these presumably are  subunits of the somatomedin-C 
receptor. In both placenta and IM-9 cells, the broad band 
corresponding to  the (3 subunit  has  a slightly slower  mobility 
(apparent M, 92,000-98,000) than  the corresponding subunit 
of the insulin receptor. In some  gels, this band appears as a 
doublet, the  faint lower component having a mobility similar 
to  the corresponding subunit of the insulin receptor. Interest- 
ingly,  in human placenta, the a subunit of the somatomedin- 
C receptor (immunoprecipitated by aIR-2 or aIR-3) has a 
slightly faster mobility (apparent M, 132,000) than  the cor- 
responding subunit of the somatomedin-C receptor from IM- 
9 cells (apparent M, 136,000) or of the insulin receptor (im- 
munoprecipitated by aIR-1 or A410) from either tissue (ap- 
parent M, 135,000). 
In order to determine with which subunit  these antibodies 
interact, immunoprecipitation studies were performed with 
iodinated placenta membrane glycoproteins that had been 
treated with dithiothreitol and SDS to dissociate receptor 
subunits (Fig. 4). After this treatment, neither subunit is 
immunoprecipitated by aIR-1, perhaps indicating that  this 
antibody recognizes an epitope that is destroyed by reduction 
and denaturation. aIR-2  and  aIR-3 specifically immunopre- 
cipitate the a subunit of the somatomedin-C receptor. A410 
immunoprecipitates both the a and @ subunits of the insulin 
receptor. Since A410 is polyclonal, this does not necessarily 
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munoprecipitates more 1251-somatomedin-C and less '=I-in- 
sulin than does aIR-3 (Fig. 1 and Table I)). Furthermore, 
aIR-2, in contrast  to  aIR-3, is retained on DEAE-cellulose 
not shown). 
The structure of insulin receptors has been extensively 
studied by a variety of techniques (7). It is  clearly  composed 
of a and p subunits with molecular  weights of approximately 
135,000 and 90,000,  respectively. Other less well characterized 
subunits have also been identified by some laboratories (6,  
products of the receptor (24-26). In Fig.  3, the only detectable 
bands specifically immunoprecipitated by aIR-1 and A410, 
which react predominantly with insulin receptors, have mo- 
lecular weights of approximately 135,000 and 90,000. 
t Information about the  structure of the somatomedin-C 
receptor is more limited and  has been obtained almost exclu- 
sively from affinity labeling studies (3, 4, 10, 11). In these 
identified which is disulfide-linked to other subunits. Evi- 
dence  for a p subunit  has been directly inferred from similar- 
- 1 2 3 4 5 6  
Mr 
x 10-3 equilibrated with 10 mM potassium phosphate, pH 8.0 (data 
I) -135 
-90 24-26). Some of these may  be precursors or degraoation 
I studies, a 135,000-molecular  weight a subunit has been  cl arly 
FIG. 4. Immunoprecipitation of reduced  and  denatured  re- 
ceptor. '251-labeled placenta glycoproteins were reduced and dena- 
tured by incubation with 1% SDS and 5 mM dithiothreitol for 5 min 
at room  temperature. The dithiothreitol was then quenched with 12 
mM N-ethylmaleimide and the denatured proteins diluted 20-fold 
with 1% albumin in 50 mM Tris. HCI, pH 7.7, containing 0.2% Triton 
X-100,l mg/ml of bacitracin, and 20 pg/ml of phenylmethylsulfonyl 
fluoride. The reduced and denatured labeled receptor was then im- 
munoprecipitated as described in  Fig.  3.  Lune I, normal mouse serum; 
lane 2, aIR-1; lane 3, aIR-2; lane 4, aIR-3; lane 5, preimmune  rabbit 
serum; lane 6, A410. 
imply  immunochemically similar sites on both subunits. Sim- 
ilar results were obtained with  labeled membrane glycopro- 
teins from IM-9 cells (data not shown). 
DISCUSSION 
The present studies describe three separate monoclonal 
antibodies which react predominantly with insulin receptors 
(aIR-1) or somatomedin-C receptors (aIR-2  and  aIR-3). We 
have interpreted the  data in Fig. 1, B C, and D as indicating 
that immunoprecipitated labeled ligand is  bound to a combi- 
nation of insulin and somatomedin-C receptors, and therefore, 
that each antibody can react with both receptors. The ability 
of aIR-1 to immunoprecipitate both insulin and somatome- 
din-C receptors is also suggested by affinity cross-linking 
studies (Fig.  2).  However, other explanations for the  data  are 
also possible. For example, the antibodies may recognize a 
third type of receptor that is distinct from both insulin and 
somatomedin-C receptors and that binds both of these ligands 
with intermediate affinity. The insulin like growth factor I1 
receptor is a possible candidate, but it probably can be ruled 
out since that receptor has little or no affinity for insulin (3, 
4), while the receptors responsible  for  labeled  ligand binding 
in Fig. 1, B, C, and D do. Furthermore, polyacrylamide gel 
electrophoresis of the immunoprecipitates of lactoperoxidase 
labeled  cells and membranes reveals  no  labeled bands in the 
220-260-kDa range (Fig. 3) which could correspond to  the 
insulin-like growth factor I1 receptor (3,4, 14). 
aIR-2  and  aIR-3 have many similar properties. Both are 
IgGI(~),  both have selectivity for somatomedin-C receptors, 
and both recognize the reduced and denatured 135,000-molec- 
ular weight subunit. However, they are clearly different anti- 
bodies. aIR-2  has more stringent specificity  for somatomedin- 
C receptors. (At the antibody concentration used, aIR-2 im- 
ities between partially reduced and unreduced  forms of the 
somatomedin-C and insulin receptors (4, 11), although in 
some affinity labeling studies, a faintly labeled  90,000-molec- 
ular weight subunit of the somatomedin-C receptor has been 
observed (4). The somatomedin-C receptor immunoprecipi- 
tated with aIR-2 and aIR-3 (Fig. 3) clearly contains both 
subunits. The /3 subunit moves  slower  on  SDS-polyacrylamide 
gels than  the corresponding subunit of the insulin receptor. 
This is fortunate because it provides a distinct method of 
distinguishing the two receptors aside from their immuno- 
chemical and ligand-binding specificities. In some  gels, the /3 
subunit of the somatomedin-C receptor appears as  a doublet, 
the  faint lower component having a mobility similar to that 
of the corresponding subunit of the insulin receptor. The 
origin of this band is not clear. It may  be due to proteolysis 
or to  a small amount of insulin receptor co-immunoprecipi- 
tated by these antibodies, or it may  be due to a microhetero- 
geneity of somatomedin-C receptor. Interestingly, the a sub- 
unit of the somatomedin-C receptor from placenta has a 
slightly more rapid mobility than  its counterpart from  IM-9 
cells. Here too, this difference may  merely result from prote- 
olysis of the receptor during preparation of the membranes, 
or it may indicate tissue specific differences in the receptors. 
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